Respiratory syncytial virus: The influence of serotype and genotype variability on clinical course of infection

International Journal of Molecular Sciences

Volumn 18, Issue 8, 2017, Pages

  Vandini, Silvia ^a   Biagi, Carlotta ^b   Lanari, Marcello ^b  

^a Imola Hospital   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Bronchiolitis; Children; Genotype; Lower respiratory tract infections; Monoclonal antibodies; Respiratory syncytial virus; Vaccines

Indexed keywords

MONOCLONAL ANTIBODY;

BRONCHIOLITIS; DISEASE SEVERITY; GENE SEQUENCE; GENETIC VARIABILITY; HOSPITALIZATION; HUMAN; INFLAMMATION; LOWER RESPIRATORY TRACT INFECTION; NONHUMAN; PATHOGENESIS; POLYMERASE CHAIN REACTION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; BLOOD; GENETIC VARIATION; GENETICS; GENOTYPE; HUMAN RESPIRATORY SYNCYTIAL VIRUS; PATHOLOGY; SEROTYPE; VIROLOGY;

GENETIC VARIATION; GENOTYPE; HUMANS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; SEROGROUP;

EID: 85026913357     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18081717     Document Type: Review

References (93)

1. Nair, H.; Nokes, D.J.; Gessner, B.D.; Dherani, M.; Madhi, S.A.; Singleton, R.J.; O’Brien, K.L.; Roca, A.; Wright, P.F.; Bruce, N.; et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010, 375, 1545-1555.
2. Anderson, E.J.; Carbonell-Estrany, X.; Blanken, M.; Lanari, M.; Sheridan-Pereira, M.; Rodgers-Gray, B.; Fullarton, J.; Rouffiac, E.; Vo, P.; Notario, G.; et al. Burden of severe respiratory syncytial virus disease among 33-35 weeks’ gestational age infants born during multiple respiratory syncytial virus seasons. Pediatr. Infect. Dis. J. 2017, 36, 160-167.
3. Iwane, M.K.; Farnon, E.C.; Gerber S.I. Importance of global surveillance for respiratory syncytial virus. J. Infect. Dis. 2013, 208, S165-S166.
4. Sigurs, N.; Aljassim, F.; Kjellman, B.; Robinson, P.D.; Sigurbergsson, F.; Bjarnason, R.; Gustafsson P.M. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax 2010, 65, 1045-1052.
5. Hall, C.B.; Weinberg, G.A.; Blumkin, A.K.; Edwards, K.M.; Staat, M.A.; Schultz, A.F.; Poehling, K.A.; Szilagyi, P.G.; Griffin, M.R.; Williams, J.V.; et al. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. J. Pediatr. 2013, 132, e341-e348.
6. Feltes, T.F.; Cabalka, A.K.; Meissner, H.C.; Piazza, F.M.; Carlin, D.A.; Top Jr., F.H.; Connor, E.M.; Sondheimer, H.M. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J. Pediatr. 2003, 143, 532-540.
7. Lanari, M.; Vandini, S.; Capretti, M.G.; Lazzarotto, T.; Faldella G. Respiratory syncytial virus infections in infants affected by primary immunodeficiency. J. Immunol. Res. 2014, 2014, 850831.
8. American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 2014, 134, e620-e638.
9. Baraldi, E.; Lanari, M.; Manzoni, P.; Rossi, G.A.; Vandini, S.; Rimini, A.; Romagnoli, C.; Colonna, P.; Biondi, A.; Biban, P.; et al. Inter-society consensus document on treatment and prevention of bronchiolitis in newborns and infants. Ital. J. Pediatr. 2014, 40, 65, doi:10.1186/1824-7288-40-65.
10. Ventre, K.; Randolph A. WITHDRAWN: Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst. Rev. 2010, 12, CD000181, doi:10.1002/14651858.CD000181.
11. Krilov, L.R. Safety issues related to the administration of ribavirin. Pediatr. Infect. Dis. J. 2002, 21, 479-481.
12. Welliver Sr, R.C. Temperature, humidity, and ultraviolet B radiation predict community respiratory syncytial virus activity. Pediatr. Infect. Dis. J. 2007, 26, S29-S35.
13. Laham, F.R.; Mansbach, J.M.; Piedra, P.A.; Hasegawa, K.; Sullivan, A.F.; Espinola, J.A.; Camargo Jr., C.A. Clinical profiles of respiratory syncytial virus subtypes A and B among children hospitalized with bronchiolitis. Pediatr. Infect. Dis. J. 2017, doi:10.1097/INF.0000000000001596.
14. Esposito, S.; Piralla, A.; Zampiero, A.; Bianchini, S.; Di Pietro, G.; Scala, A.; Pinzani, R.; Fossali, E.; Baldanti, F.; Principi, N. Characteristics and their clinical relevance of respiratory syncytial virus types and genotypes circulating in northern Italy in five consecutive winter seasons. PLoS ONE 2015, 10, e0129369, doi:10.1371/journal.pone.0129369.
15. Yoshihara, K.; Le, M.N.; Okamoto, M.; Carolle, A.; Wadagni, A. Association of RSV-A ON1 genotype with Increased Pediatric Acute Lower Respiratory Tract Infection in Vietnam. Sci. Rep. 2016, 6, 1-10.
16. Martinello, R.A.; Chen, M.D.; Weibel, C.; Kahn, J.S. Correlation between respiratory syncytial virus genotype and severity of illness. J. Infect. Dis. 2002, 186, 839-842.
17. Otieno, J.R.; Kamau, E.M.; Agoti, C.N.; Lewa, C.; Otieno, G.; Bett, A.; Ngama, M.; Cane, P.A.; Nokes, D.J. Spread and evolution of respiratory syncytial virus a genotype ON1, coastal kenya, 2010-2015. Emerg. Infect. Dis. 2017, 23, 264-271.
18. Fodha, I.; Vabret, A.; Ghedira, L.; Seboui, H.; Chouchane, S.; Dewar, J.; Gueddiche, N.; Trabelsi, A.; Boujaafar, N.; Freymuth, F. Respiratory syncytial virus infections in hospitalized infants: association between viral load, virus subgroup, and disease severity. J. Med. Virol. 2007, 79, 1951-1958.
19. McIntosh, E.D.; De Silva, L.M.; Oates, R.K. Clinical severity of respiratory syncytial virus group A and B infection in Sydney, Australia. Pediatr. Infect. Dis. J. 1993; 12, 815-819.
20. Melero, J.A.; Mas, V.; McLellan, J.S. Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development. Vaccine 2017, 35, 461-468.
21. Martínez, I.; Valdés, O.; Delfraro, A.; Arbiza, J.; Russi, J.; Melero, J.A. Evolutionary pattern of the G glycoprotein of human respiratory syncytial viruses from antigenic group B: the use of alternative termination codons and lineage diversification. J. Gen. Virol. 1999, 80, 125-130.
22. Hendry, R.M.; Talis, A.L.; Godfrey, E.; Anderson, L.J.; Fernie, B.F.; McIntosh, K. Concurrent circulation of antigenically distinct strains of respiratory syncytial virus during community outbreaks. J. Infect. Dis. 1986, 153, 291-297.
23. Venter, M.; Madhi, S.A.; Tiemessen, C.T.; Schoub, B.D. Genetic diversity and molecular epidemiology of respiratory syncytial virus over four consecutive seasons in South Africa: identification of new subgroup A and B genotypes. J. Gen. Virol. 2001, 82, 2117-2124.
24. Johnson, T.R.; Graham, B.S. Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection. Pediatr. Infect. Dis. J. 2004, 23, S46-S57.
25. White, L.J.; Waris, M.; Cane, P.A.; Nokes, D.J.; Medley, G.F. The transmission dynamics of groups A and B human respiratory syncytial virus (hRSV) in England & Wales and Finland: seasonality and cross-protection. Epidemiol. Infect. 2005, 133, 279-289.
26. Agoti, C.N.; Mwihuri, A.G.; Sande, C.J.; Onyango, C.O.; Medley, G.F.; Cane, P.A.; Nokes, D.J. Genetic relatedness of infecting and reinfecting respiratory syncytial virus strains identified in a birth cohort from rural Kenya. J. Infect. Dis. 2012, 206, 1532-1541.
27. Cane, P.A.; Matthews, D.A.; Pringle, C.R. Analysis of respiratory syncytial virus strain variation in successive epidemics in one city. J. Clin. Microbiol. 1994, 32, 1-4.
28. Peret, T.C.; Hall, C.B.; Hammond, G.W.; Piedra, P.A.; Storch, G.A.; Sullender, W.M.; Tsou, C.; Anderson, L.J. Circulation patterns of group A and B human respiratory syncytial virus genotypes in 5 communities in North America. J. Infect. Dis. 2000, 181, 1891-1896.
29. Dapat, I.C.; Shobugawa, Y.; Sano, Y.; Saito, R.; Sasaki, A.; Suzuki, Y.; Kumaki, A.; Zaraket, H; Dapat, C.; Oguma, T.; et al. New genotypes within respiratory syncytial virus group B genotype BA in Niigata, Japan. J. Clin. Microbiol. 2010, 48, 3423-3427.
30. Baek, Y.H.; Choi, E.H.; Song, M.S.; Pascua, P.N.Q.; Kwon, H.I.; Park, S.J.; Lee, J.H.; Woo, S.I.; Ahn, B.H.; Han, H.S.; et al. Prevalence and genetic characterization of respiratory syncytial virus (RSV) in hospitalized children in Korea. Arch. Virol. 2012, 157, 1039-1050.
31. Khor, C.S.; Sam, I.C.; Hooi, P.S.; Chan Y.F. Displacement of predominant respiratory syncytial virus genotypes in Malaysia between 1989 and 2011. Infect. Genet. Evol. 2013, 14, 357-360.
32. Auksornkitti, V.; Kamprasert, N.; Thongkomplew, S.; Suwannakarn, K.; Theamboonlers, A.; Samransamruajkij, R.; Poovorawan, Y. Molecular characterization of human respiratory syncytial virus, 2010-2011: Identification of genotype ON1 and a new subgroup B genotype in Thailand. Arch. Virol. 2014, 159, 499-507.
33. Pretorius, M.A.; van Niekerk, S.; Tempia, S.; Moyes, J.; Cohen, C.; Madhi, S.A. Replacement and positive evolution of subtype A and B respiratory syncytial virus G-protein genotypes from 1997-2012 in South Africa. J. Infect. Dis. 2013, 208, 227-237.
34. de-Paris, F.; Beck, C.; de Souza Nunes, L.; Pinheiro, A.M.; Paiva, R.M.; da Silva Menezes, D.; Pires, M.R.; dos Santos, R.P.; de Souza Kuchenbecker, R.; Barth, A.L. Evaluation of respiratory syncytial virus group A and B genotypes among nosocomial and community-acquired pediatric infections in Southern Brazil. Virol. J. 2014, 11, 36, https://doi.org/10.1186/1743-422X-11-36.
35. Agoti, C.N.; Otieno, J.R.; Gitahi, C.W.; Cane, P.A.; Nokes, D.J. Rapid spread and diversification of respiratory syncytial virus genotype ON1, Kenya. Emerg. Infect. Dis. 2014, 20, 950-959.
36. Tabatabai, J.; Prifert, C.; Pfeil, J.; Grulich-Henn, J.; Schnitzler, P. Novel respiratory syncytial virus (RSV) genotype ON1 predominates in Germany during winter season 2012-13. PLoS ONE 2014, 9, e109191.
37. Agoti, C.N.; Otieno, J.R.; Munywoki, P.K.; Mwihuri, A.G.; Cane, P.A.; Nokes, D.J.; Kellam, P.; Cotten M. Local evolutionary patterns of human respiratory syncytial virus derived from whole-genome sequencing. J. Virol. 2015, 89, 3444-3454.
38. Walsh, E.E.; McConnochie, K.M.; Long, C.E.; Hall, C.B. Severity of respiratory syncytial virus infection is related to virus strain. J. Infect. Dis. 1997, 175, 814-820.
39. McConnochie, K.M.; Hall, C.B.; Walsh, E.E.; Roghmann, K.J. Variation in severity of respiratory syncytial virus infections with subtype. J. Pediatr. 1990, 117, 52-62.
40. Hall, C.B.; Walsh, E.E.; Schnabel, K.C.; Long, C.E.; McConnochie, K.M.; Hildreth, S.W.; Anderson, L.J. Occurrence of groups A and B of respiratory syncytial virus over 15 years: Associated epidemiologic and clinical characteristics in hospitalized and ambulatory children. J. Infect. Dis. 1990, 162, 1283-1290.
41. Papadopoulos, N.G.; Gourgiotis, D.; Javadyan, A.; Bossios, A.; Kallergi, K.; Psarras, S.; Tsolia, M.N.; Kafetzis D. Does respiratory syncytial virus subtype influences the severity of acute bronchiolitis in hospitalized infants? Respir. Med. 2004, 98, 879-882.
42. Jafri, H.S.; Wu, X.; Makari, D.; Henrickson, K.J. Distribution of respiratory syncytial virus subtypes A and B among infants presenting to the emergency department with lower respiratory tract infection or apnea. Pediatr. Infect. Dis. J. 2013; 32, 335-340.
43. Hornsleth, A.; Klug, B.; Nir, M.; Johansen, J.; Hansen, K.S.; Christensen, L.S.; Larsen, L.B. Severity of respiratory syncytial virus disease related to type and genotype of virus and to cytokine values in nasopharyngeal secretions. Pediatr. Infect. Dis. J. 1998, 17, 1114-1121.
44. Tran, D.N.; Pham, T.M.; Ha, M.T.; Tran, T.T.; Dang, T.K.; Yoshida, L.M.; Okutsu, S.; Hayakawa, S; Mizuguchi, M.; Ushijima, H. Molecular epidemiology and disease severity of human respiratory syncytial virus in Vietnam. PLoS ONE 2013, 8, e45436.
45. Liu, W.; Chen, D.; Tan, W.; Xu, D.; Qiu, S.; Zeng, Z.; Li, X.; Zhou R. Epidemiology and clinical presentations of respiratory syncytial virus subgroups A and B detected with multiplex real-time PCR. PLoS ONE 2016, 11, e0165108.
46. Bashir, U.; Alam, M.M.; Sadia, H.; Zaidi, S.S.; Kazi, B.M. Molecular characterization of circulating respiratory syncytial virus (RSV) genotypes in Gilgit Baltistan Province of Pakistan during 2011-2012 winter season. PLoS ONE 2013, 8, e74018.
47. Eshaghi, A.; Duvvuri, V.R.; Lai, R.; Nadarajah, J.T.; Li, A.; Patel, S.N.; Low, D.E.; Gubbay, J.B. Genetic variability of human respiratory syncytial virus A strains circulating in Ontario: A novel genotype with a 72 nucleotide G gene duplication. PLoS ONE 2012, 7, e32807.
48. Luchsinger, V.; Ampuero, S.; Palomino, M.A.; Chnaiderman, J.; Levican, J.; Gaggero, A.; Larrañaga, C.E. Comparison of virological profiles of respiratory syncytial virus and rhinovirus in acute lower tract respiratory infections in very young Chilean infants, according to their clinical outcome. J. Clin. Virol. 2014, 61, 138-144.
49. Panayiotou, C.; Richter, J.; Koliou, M.; Kalogirou, N.; Georgiou, E.; Christodoulou C. Epidemiology of respiratory syncytial virus in children in Cyprus during three consecutive winter seasons (2010-2013): Age distribution, seasonality and association between prevalent genotypes and disease severity. Epidemiol. Infect. 2014, 142, 2406-2411.
50. Prifert, C.; Streng, A.; Krempl, C.D.; Liese, J.; Weissbrich, B. Novel respiratory syncytial virus a geno-type, Germany, 2011-2012. Emerg. Infect. Dis. 2013, 19, 1029-1030.
51. Larkin, E.K.; Gebretsadik, T.; Moore, M.L.; Anderson, L.J.; Dupont, W.D.; Chappell, J.D.; Minton, P.A.; Peebles Jr, R.S.; Moore, P.E.; Valet, R.S.; et al. Objectives, design and enrollment results from the infant susceptibility to pulmonary infections and asthma following RSV exposure study (inspire). BMC Pulm. Med. 2015, 15, 45, doi:10.1186/s12890-015-0040-0.
52. Wu, H.; Pfarr, D.S.; Losonsky, G.A.; Kiener, P.A. Immunoprophylaxis of RSV infection: Advancing from RSV-IGIV to palivizumab and motavizumab. Curr. Top Microbiol. Immunol. 2008, 317, 103-123.
53. García-Barreno, B.; Palomo, C.; Peñas, C.; Delgado, T.; Perez-Breña, P.; Melero, J.A. Marked differences in the antigenic structure of human respiratory syncytial virus F and G glycoproteins. J. Virol. 1989, 63, 925-932.
54. Meissner, H.C.; Groothuis, J.R.; Rodriguez, W.J.; Welliver, R.C.; Hogg, G.; Gray, P.H.; Loh, R.; Simoes, E.A.; Sly, P.; Miller, A.K.; Nichols, A.I.; Jorkasky, D.K.; Everitt, D.E.; Thompson, K.A. Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB 209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease. Antimicrob. Agents Chemother. 1999, 43, 1183-1188.
55. Beeler, J.A.; van Wyke Coelingh K. Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: Effect of mutation upon fusion function. J. Virol. 1989, 63, 2941-2950.
56. Arbiza, J.; Taylor, G.; López, J.A.; Furze, J.; Wyld, S.; Whyte, P.; Stott, E.J.; Wertz, G.; Sullender, W.; Trudel, M.; et al. Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus. J. Gen. Virol. 1992, 73, 2225-2234.
57. Null Jr, D.; Pollara, B.; Dennehy, P.H.; Steichen, J.; Sánchez, P.J.; Givner, L.B.; Carlin, D.; Landry, B.; Top Jr, F.H.; Connor, E. Safety and immunogenicity of palivizumab (Synagis) administered for two seasons. Pediatr. Infect. Dis. J. 2005, 24, 1021-1033.
58. Cabalka, A.K. Physiologic risk factors for respiratory viral infections and immunoprophylaxis for respiratory syncytial virus in young children with congenital heart disease. Pediatr. Infect. Dis. J. 2004, 23, S41-S45.
59. de Estudios Fetoneonatales, C.; Fernández, J.S.; Albas, M.D.; Satragno, D.; Cattaino, A.; Martin, A.M.; Rubio, C.; Nieto, R.; de Cardioloqía, C.; de Neumonología, N.; et al. Recommendations for palivizumab use. Update 2015. Arch. Argent. Pediatr. 2016, 114, 84-88.
60. New recommendations for the use of Synagis®, a passive immunisation to protect infants at risk of serious respiratory syncytial virus (RSV) infection. Available online: www.dh.gov.uk/ab/JCVI/DH_094744 (access on 13 July 2017).
61. Bollani, L.; Baraldi, E.; Chirico, G.; Dotta, A.; Lanari, M.; Del Vecchio, A.; Manzoni, P.; Boldrini, A.; Paolillo, P.; Di Fabio, S.; et al. Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV). Ital. J. Pediatr. 2015, 41, 97, doi:10.1186/s13052-015-0203-x.
62. CPS updates recommendations for use of palivizumab against RSV. Available online: http://www. cps.ca/en/media/release-communique/cps-updates-recommendations-for-use-of-palivizumab-against-rsv (accessed on 13 July 2017).
63. Nakazawa, M.; Saji, T.; Ichida, F.; Oyama, K.; Harada, K.; Kusuda S. Guidelines for the use of palivizumab in infants and young children with congenital heart disease. Pediatr. Int. 2006, 48, 190-193.
64. Grupo de trabajo de la Guía de Práctica Clínica sobre la Bronquiolitis Aguda. Guía de práctica clínica sobre la bronquiolitis aguda: Plan de Calidad para el Sistema Nacional de Salud (SNS) del Ministerio de Sanidad y Política Social. Guías de Práctica Clínica en el SNS, 2010, AATRM Núm. (in Spanish)
65. McLellan, J.S.; Chen, M.; Joyce, M.G.; Sastry, M.; Stewart-Jones, G.B.; Yang, Y.; Zhang, B.; Chen, L.; Srivatsan, S.; Zheng, A.; et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 2013, 342, 592-598.
66. McLellan, J.S.; Chen, M.; Leung, S.; Graepel, K.W.; Du, X.; Yang, Y.; Zhou, T.; Baxa, U.; Yasuda, E.; Beaumont, T.; et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 2013, 340, 1113-1117.
67. Kwakkenbos, M.J.; Diehl, S.A.; Yasuda, E.; Bakker, A.Q.; van Geelen, C.M.; Lukens, M.V.; van Bleek, G.M.; Widjojoatmodjo, M.N.; Bogers, W.M.; Mei, H.; et al. Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming. Nat. Med. 2010, 16, 123-128.
68. Magro, M.; Mas, V.; Chappell, K.; Vázquez, M.; Cano, O.; Luque, D.; Terrón, M.C.; Melero, J.A.; Palomo C. Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. Proc. Natl. Acad. Sci. 2012, 109, 3089-3094.
69. Griffin, M.P.; Khan, A.A.; Esser, M.T.; Jensen, K.; Takas, T.; Kankam, M.K.; Villafana, T.; Dubovsky F. Safety, tolerability, and pharmacokinetics of MED18897, the respiratory syncytial virus prefusion F-targeting monoclonal antibody with an extended half-life, in healthy adults. Antimicrob. Agents Chemother. 2017, 61, e01714-e01716.
70. Higgins, D.; Trujillo, C.; Keech C. Advances in RSV vaccine research and development-A global agenda. Vaccine 2016, 34, 2870-2875.
71. Kapikian, A.Z.; Mitchell, R.H.; Chanock, R.M.; Shvedoff, R.A.; Stewart, C.E. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol. 1969, 89, 405-421.
72. Neuzil, K.M. Progress toward a Respiratory Syncytial Virus Vaccine. Clin. Vaccine Immunol. 2016, 23, 186-188.
73. Graham, B.S. Vaccines against respiratory syncytial virus: The time has finally come. Vaccine 2016, 34, 3535-3541.
74. Green, C.A.; Scarselli, E.; Voysey, M.; Capone, S.; Vitelli, A.; Nicosia, A.; Cortese, R.; Thompson, A.J.; Sande, C.S.; de Lara, C.; Klenerman, P.; Pollard, A.J. Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins, F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults. BMJ Open 2015, 5, e008748.
75. Rey-Jurado, E.; Kalergis, A.M. Immunological Features of Respiratory Syncytial Virus-Caused Pneumonia-Implications for Vaccine Design. Int. J. Mol. Sci. 2017, 18, E556, doi:10.3390/ijms18030556.
76. Ngwuta, J.O.; Chen, M.; Modjarrad, K.; Joyce, M.G.; Kanekiyo, M.; Kumar, A.; Yassine, H.M.; Moin, S.M.; Killikelly, A.M.; Chuang, G.Y.; et al. Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci. Transl. Med. 2015, 7, 309ra162.
77. Swanson, K.A.; Settembre, E.C.; Shaw, C.A.; Dey, A.K.; Rappuoli, R.; Mandl, C.W.; Dormitzer, P.R.; Carfi A. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc. Natl. Acad. Sci. 2011, 108, 9619-9624.
78. Smith, G.; Raghunandan, R.; Wu, Y.; Liu, Y.; Massare, M.; Nathan, M.; Zhou, B.; Lu, H.; Boddapati, S.; Li, J.; et al. Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats. PLoS ONE 2012, 7, e50852.
79. Hause, A.M.; Henke, D.M.; Avadhanula, V.; Shaw, C.A.; Tapia, L.I.; Piedra, P.A. Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B. PLoS ONE 2017, 12, e0175792.
80. Glenn, G.M.; Fries, L.F.; Smith, G.; Kpamegan, E.; Lu, H.; Guebre-Xabier, M.; Hickman, S.P.; Flyer D. Modeling maternal fetal RSV F vaccine induced antibody transfer in guinea pigs. Vaccine 2015, 33, 6488-6492.
81. Ochola, R.; Sande, C.; Fegan, G.; Scott, P.D.; Medley, G.F.; Cane, P.A.; Nokes, D.J. The level and duration of RSV-specific maternal IgG in infants in Kilifi Kenya. PLoS ONE 2009, 4, e8088.
82. Stensballe, L.G.; Ravn, H.; Kristensen, K.; Meakins, T.; Aaby, P.; Simoes, E.A. Seasonal variation of maternally derived respiratory syncytial virus antibodies and association with infant hospitalizations for respiratory syncytial virus. J. Pediatr. 2009, 154, 296-298.
83. Jans, J.; Wicht, O.; Widjaja, I.; Ahout, I.M.; de Groot, R.; Guichelaar, T.; Luytjes, W.; de Jonge, M.I.; de Haan, C.A.; Ferwerda G. Characteristics of RSV-specific maternalAntibodies in plasma of hospitalized, acute RSV patients under three months of age. PLoS ONE 2017, 12, e0170877.
84. Le Saux, N.; Gaboury, I.; MacDonald N. Maternal respiratory syncytial virus antibody titers: Season and children matter. Pediatr. Infect. Dis. J. 2003, 22, 563-564.
85. McLellan, J.S.; Chen, M.; Chang, J.S.; Yang, Y.; Kim, A.; Graham, B.S.; Kwong, P.D. Structure of a major antigenic site on the respiratory syncytial virus fusion glycoprotein in complex with neutralizing antibody 101F. J. Virol. 2010, 84, 12236-12244.
86. Liljeroos, L.; Krzyzaniak, M.A.; Helenius, A.; Butcher, S.J. Architecture of respiratory syncytial virus revealed by electron cryotomography. Proc. Natl. Acad. Sci. 2013, 110, 11133-11138.
87. Krarup, A.; Truan, D.; Furmanova-Hollenstein, P.; Bogaert, L.; Bouchier, P.; Bisschop, I.J.; Widjojoatmodjo, M.N.; Zahn, R.; Schuitemaker, H.; McLellan, J.S.; et al. A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nat. Commun. 2015, 6, 8143, doi: 10.1038/ncomms9143.
88. Schneider-Ohrum, K.; Cayatte, C.; Bennett, A.S.; Rajani, G.M.; McTamney, P.; Nacel, K.; Hostetler, L.; Cheng, L.; Ren, K.; O’Day, T.; et al. Immunization with low doses of recombinant postfusion or prefusion respiratory syncytial virus f primes for vaccine-enhanced disease in the cotton rat model independently of the presence of a Th1-Biasing (GLA-SE) or Th2-Biasing (Alum) Adjuvant. J. Virol. 2017, 91, e02180-16.
89. Liang, B.; Ngwuta, J.O.; Surman, S.; Kabatova, B.; Liu, X.; Lingemann, M.; Liu, X.; Yang, L.; Herbert, R.; Swerczek, J.; et al. Improved prefusion stability, optimized codon-usage, and augmented virion packaging enhance the immunogenicity of respiratory syncytial virus (RSV) fusion protein in a vectored vaccine candidate. J. Virol. 2017, JVI.00189-17, doi:10.1128/JVI.00189-17.
90. Widjojoatmodjo, M.N.; Bogaert, L.; Meek, B.; Zahn, R.; Vellinga, J.; Custers, J.; Serroyen, J.; Radošević, K.; Schuitemaker, H. Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats. Vaccine 2015, 33, 5406-5414.
91. Zahn, R.; Saville, M. Development of a vaccine for prevention of Respiratory Syncytial Virus (RSV) disease in RSV-naïve infants. Available online: https://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsA dvisoryCommittee/UCM559670.pdf (accessed on 25 July 2017).
92. Hwang, H.S.; Kim, K.H.; Lee, Y.; Lee, Y.T.; Ko, E.J.; Park, S.; Lee, J.S.; Lee, B.C.; Kwon, Y.M.; Moore, M.L.; et al. Virus-like particle vaccines containing F or F and G proteins confer protection against respiratory syncytial virus without pulmonary inflammation in cotton rats. Hum. Vaccin. Immunother. 2017, 13, 1031-1039.
93. Karron, R.A.; Buchholz, U.J.; Collins, P.L. Live-attenuated respiratory syncytial virus vaccines. Curr. Top Microbiol. Immunol. 2013, 372, 259-284.